These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 32855207)

  • 1. Fulvestrant-Mediated Attenuation of the Innate Immune Response Decreases ER
    Abrahamsson A; Rodriguez GV; Dabrosin C
    Cancer Res; 2020 Oct; 80(20):4487-4499. PubMed ID: 32855207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib enhances the efficacy of fulvestrant by amplifying the aggregation of the estrogen receptor, which leads to a proapoptotic unfolded protein response.
    Ishii Y; Papa L; Bahadur U; Yue Z; Aguirre-Ghiso J; Shioda T; Waxman S; Germain D
    Clin Cancer Res; 2011 Apr; 17(8):2292-300. PubMed ID: 21292820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fulvestrant: a review of its use in hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy.
    McKeage K; Curran MP; Plosker GL
    Drugs; 2004; 64(6):633-48. PubMed ID: 15018596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer.
    Osipo C; Meeke K; Cheng D; Weichel A; Bertucci A; Liu H; Jordan VC
    Int J Oncol; 2007 Feb; 30(2):509-20. PubMed ID: 17203234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo.
    Ribas R; Pancholi S; Guest SK; Marangoni E; Gao Q; Thuleau A; Simigdala N; Polanska UM; Campbell H; Rani A; Liccardi G; Johnston S; Davies BR; Dowsett M; Martin LA
    Mol Cancer Ther; 2015 Sep; 14(9):2035-48. PubMed ID: 26116361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of new estrogen receptor destabilizing compounds: effects on estrogen-sensitive and tamoxifen-resistant breast cancer.
    Hoffmann J; Bohlmann R; Heinrich N; Hofmeister H; Kroll J; Künzer H; Lichtner RB; Nishino Y; Parczyk K; Sauer G; Gieschen H; Ulbrich HF; Schneider MR
    J Natl Cancer Inst; 2004 Feb; 96(3):210-8. PubMed ID: 14759988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen, flaxseed, and the lignan enterolactone increase stroma- and cancer cell-derived IL-1Ra and decrease tumor angiogenesis in estrogen-dependent breast cancer.
    Lindahl G; Saarinen N; Abrahamsson A; Dabrosin C
    Cancer Res; 2011 Jan; 71(1):51-60. PubMed ID: 21097717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
    Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
    Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of CH4893237, a new orally active estrogen receptor downregulator, on breast cancer xenograft models with low serum estrogen levels.
    Yoneya T; Tsunenari T; Taniguchi K; Kanbe Y; Morikawa K; Yamada-Okabe H; Lee YH; Lee MH; Kwon LS
    Oncol Rep; 2009 Mar; 21(3):747-55. PubMed ID: 19212635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G1T48, an oral selective estrogen receptor degrader, and the CDK4/6 inhibitor lerociclib inhibit tumor growth in animal models of endocrine-resistant breast cancer.
    Andreano KJ; Wardell SE; Baker JG; Desautels TK; Baldi R; Chao CA; Heetderks KA; Bae Y; Xiong R; Tonetti DA; Gutgesell LM; Zhao J; Sorrentino JA; Thompson DA; Bisi JE; Strum JC; Thatcher GRJ; Norris JD
    Breast Cancer Res Treat; 2020 Apr; 180(3):635-646. PubMed ID: 32130619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.
    Cook KL; Wärri A; Soto-Pantoja DR; Clarke PA; Cruz MI; Zwart A; Clarke R
    Clin Cancer Res; 2014 Jun; 20(12):3222-32. PubMed ID: 24928945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.
    Márquez-Garbán DC; Deng G; Comin-Anduix B; Garcia AJ; Xing Y; Chen HW; Cheung-Lau G; Hamilton N; Jung ME; Pietras RJ
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105415. PubMed ID: 31226312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential microRNA profiles between fulvestrant-resistant and tamoxifen-resistant human breast cancer cells.
    Zhou Q; Zeng H; Ye P; Shi Y; Guo J; Long X
    Anticancer Drugs; 2018 Jul; 29(6):539-548. PubMed ID: 29557813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.
    Santiago-Gómez A; Kedward T; Simões BM; Dragoni I; NicAmhlaoibh R; Trivier E; Sabin V; Gee JM; Sims AH; Howell SJ; Clarke RB
    Cancer Lett; 2019 Aug; 458():66-75. PubMed ID: 31121213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCL2 and CCL5 Are Novel Therapeutic Targets for Estrogen-Dependent Breast Cancer.
    Svensson S; Abrahamsson A; Rodriguez GV; Olsson AK; Jensen L; Cao Y; Dabrosin C
    Clin Cancer Res; 2015 Aug; 21(16):3794-805. PubMed ID: 25901081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer.
    Osipo C; Gajdos C; Liu H; Chen B; Jordan VC
    J Natl Cancer Inst; 2003 Nov; 95(21):1597-608. PubMed ID: 14600092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.
    Simões BM; O'Brien CS; Eyre R; Silva A; Yu L; Sarmiento-Castro A; Alférez DG; Spence K; Santiago-Gómez A; Chemi F; Acar A; Gandhi A; Howell A; Brennan K; Rydén L; Catalano S; Andó S; Gee J; Ucar A; Sims AH; Marangoni E; Farnie G; Landberg G; Howell SJ; Clarke RB
    Cell Rep; 2015 Sep; 12(12):1968-77. PubMed ID: 26387946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of SUMOylation in differential ERα transcriptional repression by tamoxifen and fulvestrant in breast cancer cells.
    Traboulsi T; El Ezzy M; Dumeaux V; Audemard E; Mader S
    Oncogene; 2019 Feb; 38(7):1019-1037. PubMed ID: 30190545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer.
    Bundred N
    Cancer Invest; 2005; 23(2):173-81. PubMed ID: 15813510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.